Hematology

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity.

Smarter therapies, evolving frailty tools, and more inclusive trials are finally extending myeloma's survival gains to older adults.

Subcutaneous mosunetuzumab simplifies the delivery of the bispecific therapy for patients with relapsed/refractory follicular lymphoma, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Beyond progression-free survival, the combination of teclistamab and daratumumab hyaluronidase-fihj showed deep clinical responses, notes Ajay K. Nooka, MD, MPH.

Galleri trial data show liquid biopsy multicancer early detection tests may cut stage IV diagnoses, despite the missed primary end point.

The findings bolster the case for using Bruton tyrosine kinase inhibitors in the treatment of Richter syndrome.

MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD.

Early treatment for acute promyelocytic leukemia likely improves mother-baby outcomes, with treatment timing guiding safer delivery.

Ajai Chari, MD, discusses how the results of the MajesTEC-3 trial may translate to a real-world second-line population with multiple myeloma.

Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.

Domain Adaptation leverages lymphoma EHRs to better predict infection risk from treatment-related immune suppression in CLL, boosting Matthews correlation coefficient.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

Teclistamab had received an accelerated approval in October 2022; the combination regimen is administered subcutaneously.

The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and potentially reshape prescribing patterns in oncology and hematology.

Patient-reported data can predict survival in leukemia, and integrating measuring tools improves care by prioritizing the patient's perspective.

Peter Voorhees, MD, explains how new daratumumab data shift smoldering multiple myeloma from watchful waiting to treatment.

Wildfire smoke from the Canadian wildfires in 2023 was linked to a higher incidence of severe strokes and increased hemorrhagic risk, according to new study findings.

A new review highlights the potential to develop ways to better anticipate and treat Richter transformation in patients with chronic lymphocytic leukemia.

Treatment for multiple myeloma often confers a higher risk of subsequent cardiovascular disease, but the impact of medications for the latter in this setting is not fully understood.

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

Mitochondrial DNA heteroplasmy is independently associated with an increased risk of CLL, suggesting potential as a novel biomarker for early risk identification.

Tina Bhatnagar, DO, speaks to the importance of diversity in clinical trials and the need to remove barriers, enroll underrepresented backgrounds, and reflect real-world health conditions.

The FDA approved acalabrutinib and venetoclax, a fixed‑duration all‑oral CLL/SLL first‑line combo, based on phase 3 AMPLIFY trial data.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Data suggest the benefits of zanubrutinib versus acalabrutinib in R/R chronic lymphocytic leukemia were even more pronounced in high-risk cases.

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals.